Generic name: ciprofloxacin hydrochloride
Dosage form: tablets, oral suspension
This dosage information does not include all the information needed to use Cipro safely and effectively. See full prescribing information for Cipro.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
CIPRO Tablets and Oral Suspension should be administered orally to adults as described in the Dosage Guidelines table.
The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative organism, the integrity of the patient's host-defense mechanisms, and the status of renal function and hepatic function.
The duration of treatment depends upon the severity of infection. The usual duration is 7 to 14 days; however, for severe and complicated infections more prolonged therapy may be required. Ciprofloxacin should be administered at least 2 hours before or 6 hours after magnesium/aluminum antacids, polymeric phosphate binders (for example, sevelamer, lanthanum carbonate) or sucralfate, Videx® (didanosine) chewable/buffered tablets or pediatric powder for oral solution, other highly buffered drugs, or other products containing calcium, iron or zinc.
|This indication is based on a surrogate endpoint, ciprofloxacin serum concentrations achieved in humans, reasonably likely to predict clinical benefit.4 For a discussion of ciprofloxacin serum concentrations in various human populations, see Inhalational Anthrax, Additional Information.|
|Urinary Tract||Acute Uncomplicated||250 mg||q 12 h||3 days|
|Mild/Moderate||250 mg||q 12 h||7 to 14 days|
|Severe/Complicated||500 mg||q 12 h||7 to 14 days|
|Chronic Bacterial||Mild/Moderate||500 mg||q 12 h||28 days|
|Lower Respiratory Tract||Mild/Moderate||500 mg||q 12 h||7 to 14 days|
|Severe/Complicated||750 mg||q 12 h||7 to 14 days|
|Acute Sinusitis||Mild/Moderate||500 mg||q 12 h||10 days|
|Skin and||Mild/Moderate||500 mg||q 12 h||7 to 14 days|
|Skin Structure||Severe/Complicated||750 mg||q 12 h||7 to 14 days|
|Bone and Joint||Mild/Moderate||500 mg||q 12 h||≥ 4 to 6 weeks|
|Severe/Complicated||750 mg||q 12 h||≥ 4 to 6 weeks|
|Intra-Abdominal†*||Complicated||500 mg||q 12 h||7 to 14 days|
|Infectious Diarrhea||Mild/Moderate/Severe||500 mg||q 12 h||5 to 7 days|
|Typhoid Fever||Mild/Moderate||500 mg||q 12 h||10 days|
|Urethral and Cervical||Uncomplicated||250 mg||single dose||single dose|
|Inhalational anthrax||500 mg||q 12 h||60 days|
Conversion of IV to Oral Dosing in Adults:
Patients whose therapy is started with CIPRO IV may be switched to CIPRO Tablets or Oral Suspension when clinically indicated at the discretion of the physician (See CLINICAL PHARMACOLOGY and table below for the equivalent dosing regimens).
|Cipro Oral Dosage||Equivalent Cipro IV Dosage|
|250 mg Tablet q 12 h||200 mg IV q 12 h|
|500 mg Tablet q 12 h||400 mg IV q 12 h|
|750 mg Tablet q 12 h||400 mg IV q 8 h|
Adults with Impaired Renal Function:
Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternative pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction. The following table provides dosage guidelines for use in patients with renal impairment:
|Creatinine Clearance (mL/min)||Dose|
|> 50||See Usual Dosage.|
|30 – 50||250 – 500 mg q 12 h|
|5 – 29||250 – 500 mg q 18 h|
|Patients on hemodialysis
or Peritoneal dialysis
|250 – 500 mg q 24 h (after dialysis)|
When only the serum creatinine concentration is known, the following formula may be used to estimate creatinine clearance.
|Men: Creatinine clearance (mL/min) =|| Weight (kg) x (140 - age)
72 x serum creatinine (mg/dL)
|Women: 0.85 x the value calculated for men.|
The serum creatinine should represent a steady state of renal function.
In patients with severe infections and severe renal impairment, a unit dose of 750 mg may be administered at the intervals noted above. Patients should be carefully monitored.
CIPRO Tablets and Oral Suspension should be administered orally as described in the Dosage Guidelines table. An increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues, has been observed. (See ADVERSE REACTIONS and CLINICAL STUDIES.)
Dosing and initial route of therapy (that is, IV or oral) for complicated urinary tract infection or pyelonephritis should be determined by the severity of the infection. In the clinical trial, pediatric patients with moderate to severe infection were initiated on 6 to 10 mg/kg IV every 8 hours and allowed to switch to oral therapy (10 to 20 mg/kg every 12 hours), at the discretion of the physician.
|Infection||Route of Administration||Dose
|Complicated Urinary Tract or Pyelonephritis
(patients from 1 to 17 years of age)
|Intravenous||6 to 10 mg/kg
(maximum 400 mg per dose; not to be exceeded even in patients weighing > 51 kg)
|Every 8 hours||
|Oral||10 mg/kg to 20 mg/kg
(maximum 750 mg per dose; not to be exceeded even in patients weighing > 51 kg)
|Every 12 hours|
(maximum 400 mg per dose)
|Every 12 hours||
(maximum 500 mg per dose)
|Every 12 hours|
Pediatric patients with moderate to severe renal insufficiency were excluded from the clinical trial of complicated urinary tract infection and pyelonephritis. No information is available on dosing adjustments necessary for pediatric patients with moderate to severe renal insufficiency (that is, creatinine clearance of < 50 mL/min/1.73m2).
- Cipro Side Effects
- Cipro Drug Interactions
- Cipro (ciprofloxacin) consumer information
- Cipro XR (ciprofloxacin) tablet, film coated dosage information
- Ciprofloxacin dosage information
- Ciprofloxacin consumer information
- Proquin XR (ciprofloxacin hydrochloride) tablet, film coated, extended release dosage information
- Proquin XR (ciprofloxacin) consumer information